Marco Galluzzo

69PUBLICATIONS
130CO-AUTHORS
PharmacogenomicsRegenerative medicine (incl. stem cells)AllergyRheumatology and arthritisMedical biochemistry - lipids
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (69)

|Apr 15, 2026
Dupilumab for prurigo nodularis: real-world outcomes up to 104 weeks from the Dupilumab Italian Prurigo Nodularis (DUPItaPN) study.

|Mar 13, 2026
AVT04, a Biosimilar to Reference Product Ustekinumab, for the Treatment of Plaque Psoriasis: Insights from a Real-World Experience up to 28 Weeks.

Edoardo Mortato, Marina Talamonti, Lorenzo Savastano

|Feb 19, 2026
Psychological Well-Being of Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab: 28-Week Interim Results from a Multicenter Observational Study in Italy Using the DASS-21 Questionnaire, the BLUE Study.

Emanuele Trovato, Claudio Bonifati, Simone Ribero

|Jan 28, 2026
Long-Term Impact of Guselkumab on Systemic Inflammation Indices in Moderate-to-Severe Psoriasis.

Edoardo Mortato, Lorenzo Marcelli, Agostino Panichelli

|Nov 03, 2025
Baricitinib for adult atopic dermatitis: real-world effectiveness, safety, and response predictors.

Niccolò Gori, Lucia Di Nardo, Elena Ippoliti

|Sep 22, 2025
Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study.

Edoardo Mortato, Marina Talamonti, Lorenzo Marcelli

Pageof 12

Frequent Collaborators

37 joint publications

Marina Talamonti

18 joint publications

Luca Bianchi

9 joint publications

Andrea Chiricozzi

8 joint publications

Giacomo Caldarola